ONCY Stock Summary and Trading Ideas (Oncolytics Biotech | NASDAQ:ONCY)

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Oncolytics Biotech trades on the NASDAQ stock market under the symbol ONCY.

As of September 4, 2026, ONCY stock price declined to $0.84 with 455,630 million shares trading.

ONCY has a beta of 2.18, meaning it tends to be more sensitive to market movements. ONCY has a correlation of 0.13 to the broad based SPY ETF.

ONCY has a market cap of $107.52 million. This is considered a Micro Cap stock.

In the last 3 years, ONCY traded as high as $2.42 and as low as $.33.

The top ETF exchange traded funds that ONCY belongs to (by Net Assets): QQQS.

ONCY has underperformed the market in the last year with a price return of -21.9% while the SPY ETF gained +19.8%. ONCY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.7% and 0.0%, respectively, while the SPY returned +2.0% and +0.6%, respectively.

ONCY support price is $.83 and resistance is $.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONCY shares will trade within this expected range on the day.